|
End-of-day quote
Korea S.E.
28/10/2026
|
5-day change | 1st Jan Change | ||
| 16,300.00 KRW | +2.00% |
|
-3.89% | -71.60% |
| 07-23 | Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell | MT |
| 12-22 | IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index | CI |
Company Valuation: IntoCell, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 |
|---|---|
| Market Cap 1 | 861,052 |
| Change | - |
| Enterprise Value (EV) 1 | 840,466 |
| Change | - |
| P/E | -77.1x |
| PBR | 34.8x |
| PEG | 48.66x |
| Capitalization / Revenue | 374,513,177x |
| EV / Revenue | - |
| EV / EBITDA | -88.2x |
| EV / EBIT | -81.6x |
| EV / FCF | -132x |
| FCF Yield | -0.76% |
| Dividend per Share 2 | - |
| Rate of return | - |
| EPS 2 | -744 |
| Distribution rate | - |
| Net sales | 2,299 |
| EBITDA 1 | -9,526 |
| EBIT 1 | -10,300 |
| Net income 1 | -10,603 |
| Net Debt 1 | -20,586 |
| Reference price 2 | 57,400.00 |
| Nbr of stocks (in thousands) | 15,001 |
| Announcement Date | 01/03/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 181M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 26.88x | 26.33x | 15.57x | 0.34% | 38.06B | |
| Weighted average by Cap. | 26.55x | 25.23x | 15.68x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A287840 Stock
- Valuation IntoCell, Inc.
Select your edition
All financial news and data tailored to specific country editions
